A 12-month, single-blind, randomized, parallel group, multicenter study to investigate the efficacy and safety of ERL080A compared with MMF in de novo heart recipients.

Trial Profile

A 12-month, single-blind, randomized, parallel group, multicenter study to investigate the efficacy and safety of ERL080A compared with MMF in de novo heart recipients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Mycophenolate sodium (Primary) ; Mycophenolate mofetil
  • Indications Heart transplant rejection
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 01 Nov 2011 Actual end date of the extension trial (NCT00238446) is Jun 2006.
    • 01 Nov 2011 Actual end date of the extension trial (NCT00238446) is Jun 2006.
    • 01 Nov 2011 Actual initiation date of the extension trial (NCT00238446) is Apr 2003.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top